US5085629A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Biodegradable stent
Assignee: Cabot Technology Corp
•
Filing: 1989-09-27
•
Granted: 1992-02-04
•
Expires: 2009-09-27
Abstract
Abstract A biodegradable, biocompatible, resorbable infusion stent comprising a terpolymer of: (a) L(-)lactide, (b) glycolide, and (c) epsilon-caprolactone. This invention includes a method for treating ureteral obstructions or impairments by utilizing a biodegradable, biocompatible, resorbable infusion stent, and a method for controlling the speed of resorption of the stent.
Inventors
- 👤 Jay Goldberg
- 👤 Richard Sinclair
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 14:51
CPC Classifications
A; A61; A61F; A61F2/00; A61F2/82; A61F2/94; A61L; A61L31/00; A61L31/04; A61L31/06; A61L31/14; A61L31/148; A61B; A61B90/00; A61B90/39; A61F2/02; A61F2/04; A61F2002/048; A61F2210/00; A61F2210/0004; A61F2250/00; A61F2250/0058; A61F2250/0096; A61F2250/0098
Claims Analysis
Total Claims: 36
Claim 1
Independent Claim
33 words
A biodegradable, biocompatible, resorbable, ureteral stent having retaining means to prevent migration from a predetermined position in the ureter, said stent comprising a terpolymer of: (a) L(-) lactide (b) glycolide, and (c) epsilon-caprolactone.
Claim 2
Dependent Claim
33 words
A biodegradable, biocompatible, resorbable, ureteral stent having retaining means to prevent migration from a predetermined position in the ureter, said stent comprising a terpolymer of: (a) L(-) lactide (b) glycolide, and (c) epsilon-caprolactone.
Claim 3
Dependent Claim
17 words
The ureteral stent of claim 1, wherein the epsilon-caprolactone varies from about 15 to 25 weight %.
Claim 4
Dependent Claim
17 words
The ureteral stent of claim 1, wherein the L(-)lactide varies from about 45 to 85 weight %.
Claim 5
Dependent Claim
17 words
The ureteral stent of claim 1, wherein the glycolide varies from about 5 to 50 weight %.
Claim 6
Dependent Claim
18 words
The ureteral stent of claim 1, also including about 5 to 30 weight % of a radiopaque material.
Claim 7
Dependent Claim
15 words
The ureteral stent of claim 5, wherein said radiopaque material is finely divided barium sulfate.
Claim 8
Dependent Claim
16 words
The ureteral stent of claim 1, wherein the modulus varies from about 6000 to 7000 psi.
Claim 9
Dependent Claim
15 words
The ureteral stent of claim 1, bendable into a pliable curl set at each end.
Claim 10
Dependent Claim
14 words
The ureteral stent of claim 1, sterilizable and capable of compounding with radiopaque materials.
Claim 11
Dependent Claim
9 words
The ureteral stent of claim 1, in transparent form.
Claim 12
Dependent Claim
21 words
The ureteral stent of claim 1, wherein the terpolymer has a weight average molecular weight varying from about 20,000 to 1,000,000.
Claim 13
Dependent Claim
23 words
The ureteral stent of claim 1, wherein the terpolymer has a melt process decomposition temperature greater than or equal to about 230° C.
Claim 14
Dependent Claim
23 words
The ureteral stent of claim 1, wherein the terpolymer has a tube extrusion processing temperature that varies from about 135° to 150° C.
Claim 15
Dependent Claim
20 words
The ureteral stent of claim 11, wherein, the terpolymer has a weight average molecular weight of about 50,000 to 400,000.
Claim 16
Dependent Claim
34 words
The ureteral stent of claim 1, having: (i) a tensile strength of at least about 500 psi, (ii) an elongation greater than about 10%, and (iii) Shore A hardness of about 50 to 100.
Claim 17
Independent Claim
61 words
A method for treating ureteral obstruction or impairment in a mammalian host by inserting in the ureter in a predetermined location, a biodegradable, biocompatible resorbable non-anastomosis polymeris stent extending between the kidney and the bladder, said stent having end portions with pliable retaining means to prevent migration before biodegradation, without the need for suturing, from the predetermined location in the ureter.
Claim 18
Independent Claim
61 words
A method for treating ureteral obstruction or impairment in a mammalian host by inserting in the ureter in a predetermined location, a biodegradable, biocompatible resorbable non-anastomosis polymeris stent extending between the kidney and the bladder, said stent having end portions with pliable retaining means to prevent migration before biodegradation, without the need for suturing, from the predetermined location in the ureter.
Claim 19
Dependent Claim
39 words
The method of claim 16, wherein said stent has the following properties: (i) a tensile strength of at least about 500 psi, (ii) an elongation greater than about 10%, and (iii) Shore A hardness of about 50 to 100.
Claim 20
Dependent Claim
34 words
The method of claim 16, wherein the stent has the following properties: (a) tensile strength greater than 1000 psi, (b) elongation greater than 100%, and (c) Shore A hardness of about 75 to 95.
Claim 21
Dependent Claim
24 words
The method of claim 16, wherein said stent comprises a polymeric material having a weight average molecular weight varying from about 50,000 to 400,000.
Claim 22
Dependent Claim
27 words
The method of claim 16, wherein the stent comprises at least one polymer selected from the group consisting of L(-)lactide, glycolide, epsilon-caprolactone, D(-)lactide, meso-lactide, D,L-lactide, and delta-valero-lactone.
Claim 23
Dependent Claim
19 words
The method of claim 29, wherein the stent comprises of terpolymer of: (a) L(-)lactide, (b) glycolide, and (c) epsilon-caprolactone.
Claim 24
Dependent Claim
16 words
The method of claim 21, wherein the L(-)lactide varies from about 45 to 85 weight %.
Claim 25
Dependent Claim
16 words
The method of claim 21, wherein the glycolide varies from about 5 to 50 weight %.
Claim 26
Dependent Claim
16 words
The method of claim 21, wherein the epsilon-caprolactone varies from about 15 to 25 weight %.
Claim 27
Independent Claim
109 words
A method for controlling the time of biodegradation in the ureter of a polymeric, biodegradable, biocompatible, resorbable non-anastomosis ureteral stent by (a) inserting a stent in the ureter in a predetermined location between the kidney and the bladder to relieve ureteral obstruction; (b) providing end portions of the stent with pliable retaining means to prevent migration of the stent before biodegradation, without the need for suturing; and (c) controlling the rate of biodegradation of said polymeric stent from a few weeks to a few months, by varying the molecular weight of the polymer composition comprising the stent, from a weight average molecular weight of about 20,000 to about 1,000,000.
Claim 28
Independent Claim
109 words
A method for controlling the time of biodegradation in the ureter of a polymeric, biodegradable, biocompatible, resorbable non-anastomosis ureteral stent by (a) inserting a stent in the ureter in a predetermined location between the kidney and the bladder to relieve ureteral obstruction; (b) providing end portions of the stent with pliable retaining means to prevent migration of the stent before biodegradation, without the need for suturing; and (c) controlling the rate of biodegradation of said polymeric stent from a few weeks to a few months, by varying the molecular weight of the polymer composition comprising the stent, from a weight average molecular weight of about 20,000 to about 1,000,000.
Claim 29
Dependent Claim
19 words
The method of claim 25, wherein the stent comprises a terpolymer of: (a) L(-)lactide, (b) glycolide, and (c) epsilon-caprolactone.
Claim 30
Dependent Claim
22 words
The method of claim 25, wherein the weight average molecular weight of said polymeric stent varies from about 50,000 to about 400,000.
Claim 31
Dependent Claim
27 words
The method of claim 25, wherein the stent comprises at least one polymer selected from the group consisting of L(-)lactide, glycolide, epsilon-caprolactone, D(-)lactide, meso-lactide, D,L-lactide, and delta-valero-lactone.
Claim 32
Dependent Claim
17 words
The method of claim 25, wherein the average molecular weight varies from about 50,000 to about 400,000.
Claim 33
Dependent Claim
39 words
The method of claim 25, wherein said stent has the following properties: (i) a tensile strength of at least about 500 psi, (ii) an elongation greater than about 10%, and (iii) Shore A hardness of about 50 to 100.
Claim 34
Independent Claim
113 words
A method for relieving ureteral obstruction in a mammalian host, comprising: (a) forming a tubular polymeric, biodegradable, biocompatible resorbable non-anastomosis ureteral stent having end portions with pliable retaining means to prevent migration before biodegradation, without the need for suturing, from a predetermined position in the ureter, and wherein said stent substantially extends from the kidney to the bladder; (b) controlling the rate of biodegradation of said polymeric stent by varying the molecular weight of the polymer composition comprising the stent, from a weight average molecular weight of about 50,000 to about 1,000,000, and (c) inserting said positioning said ureteral stent in the ureter in a predetermined location between the kidney and the bladder.
Claim 35
Independent Claim
113 words
A method for relieving ureteral obstruction in a mammalian host, comprising: (a) forming a tubular polymeric, biodegradable, biocompatible resorbable non-anastomosis ureteral stent having end portions with pliable retaining means to prevent migration before biodegradation, without the need for suturing, from a predetermined position in the ureter, and wherein said stent substantially extends from the kidney to the bladder; (b) controlling the rate of biodegradation of said polymeric stent by varying the molecular weight of the polymer composition comprising the stent, from a weight average molecular weight of about 50,000 to about 1,000,000, and (c) inserting said positioning said ureteral stent in the ureter in a predetermined location between the kidney and the bladder.
Claim 36
Dependent Claim
39 words
The method of claim 31, wherein said stent has the following properties: (i) a tensile strength of at least about 500 psi, (ii) an elongation greater than about 10%, and (iii) Shore A hardness of about 50 to 100.
References Cited (Backward Citations)
US4045418A
Cited
US4300565A
Cited
US4212304A
Cited
US4379138A
Cited
US4700704A
Cited
US4605730A
Cited
US4531933A
Cited
US4610657A
Cited
US4650488A
Cited
US4674506A
Cited
US4863472A
Cited
US4791929A
Cited
US4826945A
Cited
US4916193A
Cited
US4874360A
Cited
US4994074A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1995-02-03 | 1995-08-05 | 1996-02-04 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1999-02-03 | 1999-08-05 | 2000-02-04 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2003-02-03 | 2003-08-05 | 2004-02-04 | $7700.00 | Window Closed / Lapsed |